DB17788InvestigationalProtein Based Therapies
Rivabazumab pegol is being investigated as a treatment of Pseudomonas aeruginosa lung infections in patients with cystic fibrosis.
- Also known as
- IMMUNOGLOBULIN FAB' G1-KAPPA PEGYLATED, ANTI-PSEUDOMONAS AERUGINOSA TYPE III SECRETION SYSTEM (TTSS)PCRV PROTEIN, PEGYLATED HUMANIZED MONOCLONAL ANTIBODY · KB001-A · KB001-A (AN ANTI-PCRV PEGYLATED MONOCLONAL ANTIBODY FRAGMENT TO THE TYPE III SECRETION SYSTEM OF PSEUDOMONAS AERUGINOSA) · PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Rivabazumab pegol, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account